Business Context and Reporting Period
This Form 8-K reports on events occurring on June 15, 2021, regarding Aileron Therapeutics, Inc. (Note: The request metadata listed "Rein Therapeutics," but the filing text explicitly identifies the registrant as Aileron Therapeutics, Inc., trading under symbol ALRN). The report details the outcomes of the Company's 2021 Annual Meeting of Stockholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity structure. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial statement line items.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to the Restated Certificate of Incorporation, increasing authorized common stock from 150,000,000 to 300,000,000 shares. The amendment was filed with the Delaware Secretary of State on June 16, 2021.
- Stock Incentive Plan: Stockholders approved the Aileron Therapeutics, Inc. 2021 Stock Incentive Plan.
- Director Elections: Jeffrey A. Bailey and Jodie P. Morrison were elected as Class I directors for a three-year term expiring in 2024.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Voting Results Summary
| Matter | For | Against | Abstain/Withheld | Broker Non-Votes |
|---|---|---|---|---|
| Election of Jeffrey A. Bailey | 34,871,045 | - | 1,402,787 (Withheld) | 21,524,472 |
| Election of Jodie P. Morrison | 34,953,516 | - | 1,320,316 (Withheld) | 21,524,472 |
| Amendment to Increase Authorized Shares | 55,870,814 | 1,546,962 | 380,528 | - |
| 2021 Stock Incentive Plan | 31,937,478 | 4,210,849 | 125,505 | 21,524,472 |
| Ratification of Auditor (PwC) | 57,626,598 | 141,963 | 29,743 | - |
Guidance, Outlook, and Risks
This filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. It is a procedural report confirming the successful passage of shareholder proposals.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Amendment (filed June 16, 2021) to confirm the new authorized share count of 300,000,000.
- Review the full text of the 2021 Stock Incentive Plan (Exhibit 99.1) to understand dilution potential and vesting terms.
- Note the significant number of broker non-votes (approx. 21.5 million) on director elections and the incentive plan, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the identity of the registrant as Aileron Therapeutics, Inc., distinct from the "Rein Therapeutics" name in the request metadata.